Abstract:We reviewed 173 patients with an initial diagnosis of peripheral T-cell non-Hodgkin lymphoma (PTCL) and compared the patients with bone marrow involvement (BMI) to those without to have a better understanding of the clinical characteristics, treatments, survival and prognosis of PTCLs with BMI. We found that 40% (70/173) of the patients had BMI, and its frequency was 64% in angioimmunoblastic T-cell lymphoma (TCL), 46% in PTCL unspecified, 29% in anaplastic large T-cell lymphoma, 23% in extranodal NK/T-cell lymphoma and 13% in enteropathy-type TCL. In the BMI group, 36% of patients had lymphoma-associated hemophagocytic syndrome (LAHS), compared with 8% of the patients without BMI (8/103, P < 0.001). The estimated 1-year overall survival (OS) rates of patients with LAHS in the BMI and non-BMI groups were 5 and 49%, respectively. The increased levels of lactate dehydrogenase, fasting triglycerides and β2-microglobulin between the BMI and non-BMI groups were not significantly different, but ferritin increased significantly and liver dysfunction-related diseases were seen more in the BMI group. As much as 51% of patients of the BMI group had anemia, compared with 27% of the patients without BMI (P = 0.001). The estimated 2-year OS rates in the two groups were 10 and 34%. The estimated 2-year OS rate of the 67 patients with BMI, who did not lose to follow-up, was 22%, compared with 38% in the non-BMI group. The median survival times of the 2 groups were 120 and 356 days. The estimated 2-year OS rate of patients treated by CHOP regimen was 9%, compared with 51% of those with intensive chemotherapy, with a significant difference (log rank P = 0.0008). The median survival time of the 14 patients subjected to chemotherapy combined with l-asparaginase was 365 days and that of the 7 patients undergoing hemopoietic stem cell transplantation (HSCT) was 575 days. A total of 3 patients in a critical condition underwent plasmapheresis as initial therapy and achieved stable condition. We conclude that patients with PTCLs with BMI on initial diagnosis usually have hemaphagocytic syndrome and poor prognosis. BMI without lymphadenopathy is a patent clinical feature in most PTCLs. Patients with anemia on initial diagnosis in the BMI group usually have poor prognosis than those without. Intense chemotherapy, addition of l-asparaginase in chemotherapy and HSCT are comparatively efficient treatments of PTCLs. For patients in critical conditions, plasmapheresis before chemotherapy would lower the risk and improve the tolerance to chemotherapy.

Clinical Characterization and Prognostic Factors of Primary Lymphoma of Bone in Case of Chinese Patients

Clinical Characterization and Outcome of Primary Bone Lymphoma: a Retrospective Study of 61 Chinese Patients

Clinical and Histological Features of Primary Testicular Diffuse Large B-cell Lymphoma: a Single Center Experience in China

Significance of Clinical Factors As Prognostic Indicators for Mature T-Cell Non-Hodgkin Lymphoma Patients: A Retrospective Analysis of Chinese Cases

Primary Lymphoma of Bone: a Population-Based Study of 2558 Patients.

Clinical Features and Treatment of Primary Non-Hodgkin Lymphoma of Bone

Clinicopathological Study on Peripheral T-cell Non-Hodgkin Lymphoma with Bone Marrow Involvement: a Retrospective Analysis from China.

[Clinical Features of 11 Cases of Primary Bone Lymphoma].

Primary lymphoma of bone:report of one case and review of literature

Clinical analysis of primary bone lymphoma:report of 42 cases

Primary lymphoma of bone: a case report and review of the literature

[Clinical Analysis of 13 Patients with Primary Bone Lymphoma].

Primary lymphoma of bone:A clinicopathologic and immunohistochemical observation

Clinicopathological Features and Prognostic Factors of Rare Primary Bone Marrow Diffuse Large B Cell Lymphoma

Clinical and prognostic analysis of 21 cases of primary breast lymphoma

Clinical Features and Prognostic Factors of Primary Bone Marrow Lymphoma

Clinical and pathological characteristics of primary bone lymphoma

Prognostic Factors and Treatment Efficacy in Patients with Primary Diffuse Large B-cell Lymphoma of the Bone: Single Institute Experience over 11 Years.

Primary mediastinal large B-cell lymphoma (PMLBCL) in Chinese patients: clinical characteristics and prognostic factors

Outcomes and Prognostic Factors in Patients with Primary Bone Lymphoma

Primary Malignant Lymphoma of the Breast: a Study of 15 Cases and Review of the Chinese Literature